Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBITDA (2020 - 2025)

Historic EBITDA for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$11.0 million.

  • Insight Molecular Diagnostics' EBITDA rose 1825.38% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 4065.56%. This contributed to the annual value of -$61.0 million for FY2024, which is 14284.29% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its EBITDA stood at -$11.0 million for Q3 2025, which was up 1825.38% from -$9.8 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' EBITDA peaked at $5.8 million during Q1 2023, and registered a low of -$35.7 million during Q4 2021.
  • Moreover, its 5-year median value for EBITDA was -$9.9 million (2022), whereas its average is -$11.2 million.
  • In the last 5 years, Insight Molecular Diagnostics' EBITDA crashed by 46933.14% in 2021 and then soared by 15912.08% in 2023.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' EBITDA stood at -$35.7 million in 2021, then surged by 67.35% to -$11.6 million in 2022, then crashed by 38.9% to -$16.2 million in 2023, then plummeted by 107.84% to -$33.6 million in 2024, then surged by 67.15% to -$11.0 million in 2025.
  • Its EBITDA was -$11.0 million in Q3 2025, compared to -$9.8 million in Q2 2025 and -$6.8 million in Q1 2025.